MX2018011793A - Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b. - Google Patents

Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.

Info

Publication number
MX2018011793A
MX2018011793A MX2018011793A MX2018011793A MX2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
virus
hepatitis
antigen
antigens
Prior art date
Application number
MX2018011793A
Other languages
English (en)
Inventor
Cesar Aguilar Rubido Julio
Lobaina Mato Yadira
Iglesias Perez Enrique
Penton Arias Eduardo
Enrique Guillén Nieto Gerardo
Agustin Aguiar Santiago Jorge
Gonzalez Blanco Sonia
Valdes Hernandez Jorge
Vazquez Castillo Mariela
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2018011793A publication Critical patent/MX2018011793A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion revela una composicion farmaceutica que comprende el antigeno de la superficie (HBsAg) del virus de la hepatitis B (VHB) y el antigeno de la nucleocapsida (o core, HBcAg) del propio virus; el HBcAg presente en dicha composicion contiene acido ribonucleico mensajero (ARNm) en una proporcion superior al 45% del total de acido ribonucleico (ARN) de dicho antigeno; debido a cambios en la constitucion de los antigenos que la componen, la composicion de la invencion es util para la prevencion o el tratamiento de la hepatitis B cronica; tambien contempla el uso de esa composicion farmaceutica en la manufactura de un medicamento para la inmunoprofilaxis o la inmunoterapia contra la infeccion por VHB, y su uso para incrementar la respuesta inmune contra un antigeno adicional que se co-administra con la mezcla de dichos antigenos.
MX2018011793A 2016-03-31 2017-03-14 Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b. MX2018011793A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (1)

Publication Number Publication Date
MX2018011793A true MX2018011793A (es) 2018-12-17

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011793A MX2018011793A (es) 2016-03-31 2017-03-14 Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.

Country Status (17)

Country Link
US (2) US11491218B2 (es)
EP (1) EP3437654B1 (es)
JP (1) JP6981992B2 (es)
KR (1) KR20180125985A (es)
CN (1) CN109219449B (es)
AR (1) AR108009A1 (es)
AU (1) AU2017243136B2 (es)
BR (1) BR112018069738A2 (es)
CA (1) CA3017778A1 (es)
CU (1) CU24454B1 (es)
EA (1) EA201892212A1 (es)
ES (1) ES2965709T3 (es)
HK (1) HK1259329A1 (es)
MX (1) MX2018011793A (es)
TW (1) TWI755383B (es)
WO (1) WO2017167317A1 (es)
ZA (1) ZA201806325B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20200028A7 (es) 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
CN116218881A (zh) * 2022-10-21 2023-06-06 山东大学 一种治疗或者预防乙肝病毒的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN104338132A (zh) * 2013-07-26 2015-02-11 复旦大学 一种病毒免疫治疗药物复合物及其用途

Also Published As

Publication number Publication date
TW201735945A (zh) 2017-10-16
US11759517B2 (en) 2023-09-19
AU2017243136A1 (en) 2018-10-11
EP3437654B1 (en) 2023-09-20
EA201892212A1 (ru) 2019-03-29
KR20180125985A (ko) 2018-11-26
EP3437654A1 (en) 2019-02-06
ZA201806325B (en) 2020-08-26
CN109219449B (zh) 2022-08-30
CN109219449A (zh) 2019-01-15
ES2965709T3 (es) 2024-04-16
US11491218B2 (en) 2022-11-08
TWI755383B (zh) 2022-02-21
CA3017778A1 (en) 2017-10-05
JP2019510064A (ja) 2019-04-11
JP6981992B2 (ja) 2021-12-17
AR108009A1 (es) 2018-07-04
US20200297840A1 (en) 2020-09-24
WO2017167317A1 (es) 2017-10-05
CU20160038A7 (es) 2017-11-07
AU2017243136B2 (en) 2022-02-17
US20220193228A1 (en) 2022-06-23
CU24454B1 (es) 2019-11-04
BR112018069738A2 (pt) 2019-02-05
HK1259329A1 (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
HRP20172003T1 (hr) Toll-like receptor koji modulira spojeve 4,6-diamino-pirido[3,2-d]pirimidina
WO2018195165A8 (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
HK1248681A1 (zh) 作為hbsag(hbv表面抗原)和hbv dna生成的抑制劑用於治療乙型肝炎病毒感染的四氫吡啶並嘧啶和四氫吡啶並吡啶類化合物
PH12017500614A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
JOP20190015A1 (ar) عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
MX2020011804A (es) Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.
WO2016183366A3 (en) Compositions and methods for silencing expression of hepatitis d virus rna
EA201290556A1 (ru) Оральная лекарственная форма, включающая энтекавир
MX2018011793A (es) Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.
MY178496A (en) Antibody composition for prevention or treatment of mutant hepatitis b virus infection
WO2011150320A3 (en) Activators of innate immunity
PH12020500176A1 (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
WO2016200113A3 (ko) 녹차 추출물에 의해 불화된 바이러스를 포함하는 백신 및 그의 제조방법
JP2019510064A5 (es)
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine
MX2020001055A (es) Vacuna contra la malaria.
UY31574A1 (es) Vacunas contra la malaria
WO2018066891A3 (ko) 인터페론 베타 변이체의 안정화 제제
EP3986459A4 (en) IMPROVED THERAPEUTIC COMPOSITION CONTAINING HEPATITIS B ANTIGEN HAVING S, PRE-S1 AND PRE-2 PROTEINS, ALUMINUM PHOSPHATE AND ALPHA INTERFERON AND USE IN THE TREATMENT OF HEPATITIS B
GR1008805B (el) Στερεο φαρμακευτικο σκευασμα περιεχον χαμηλη δοση εντεκαβιρης και μεθοδος παρασκευης αυτου